The Catabasis Pharmaceuticals (CATB) Getting Positive Media Coverage, AlphaOne Reports

The Catabasis Pharmaceuticals (CATB) Getting Positive Media Coverage, AlphaOne Reports

Here are some of the news stories that may have effected AlphaOne’s rankings:

Media coverage about Catabasis Pharmaceuticals (NASDAQ:CATB) has been trending positive on Monday, according to Alpha One Sentiment Analysis. Alpha One, a division of Accern, identifies negative and positive media coverage by analyzing more than twenty million blog and news sources. Alpha One ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Catabasis Pharmaceuticals earned a coverage optimism score of 0.38 on Alpha One’s scale. Alpha One also gave press coverage about the biotechnology company an impact score of 0 out of 100, meaning that recent media coverage is extremely unlikely to have an impact on the stock’s share price in the near term.

A number of equities research analysts have issued reports on the stock. Oppenheimer Holdings Inc. set a $11.00 target price on shares of Catabasis Pharmaceuticals and gave the company a “buy” rating in a report on Saturday, March 18th. Zacks Investment Research cut shares of Catabasis Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, February 6th. Wedbush reaffirmed an “ourperform” rating and issued a $4.00 price target on shares of Catabasis Pharmaceuticals in a report on Monday, May 15th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $8.00 price target (down previously from $14.00) on shares of Catabasis Pharmaceuticals in a report on Tuesday, March 21st. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Catabasis Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $5.30. Catabasis Pharmaceuticals (CATB) opened at 1.36 on Monday. The stock’s market capitalization is $30.56 million. Catabasis Pharmaceuticals has a 12 month low of $1.08 and a 12 month high of $7.89. The company has a 50-day moving average of $1.39 and a 200 day moving average of $2.35.

Catabasis Pharmaceuticals (NASDAQ:CATB) last issued its earnings results on Thursday, March 16th. The biotechnology company reported ($0.47) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.49) by $0.02. On average, equities research analysts anticipate that Catabasis Pharmaceuticals will post ($1.55) earnings per share for the current fiscal year. About Catabasis Pharmaceuticals

Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:CATB”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Related posts

Leave a Comment